Compare Teradyne, Inc. (TER) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Teradyne, Inc. vs TransMedics Group Inc — how do they compare? Teradyne, Inc. trades at $402.1 (market cap $62.34B), while TransMedics Group Inc trades at $77.75 (market cap $2.74B). The key difference: Teradyne, Inc. is far larger — about 22.8× TransMedics Group Inc's market cap, and Teradyne, Inc. pays a 0.13% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Teradyne, Inc. for 37 Days and TransMedics Group Inc for 24 Days on average.
| TER | TMDX | |
|---|---|---|
Market Cap | $62.34B | $2.74B |
Volume | 3,368,404 | 949,331 |
Sector | Technology | Health |
52-Week High | $483.84 | $150.42 |
52-Week Low | $132.05 | $61.99 |
Typical Hold Time | 37 Days | 24 Days |
Enterprise Value | $62.08B | $3.13B |
Dividend Yield | 0.13% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Teradyne (TER) trades at $403.88, down 1.92% on the day, yet maintains a bullish technical stance with strong analyst support. The company exhibits robust profitability with a 25.77% net income margin and 36.66% ROE, supported by consecutive earnings beats. Recent news highlights expansion in AI-driven test equipment, including the Magnum E2 and Iris 100 platforms, positioning TER to capitalize on semiconductor and data center demand growth.
The outlook is positive, driven by strategic product launches and strong earnings momentum, with a consensus price target of $461.50 implying ~14% upside. Key risks include execution challenges in a competitive semiconductor equipment market and sensitivity to cyclical industry demand, which could pressure valuation multiples if growth slows.
TransMedics Group (TMDX) trades at $80.69, down 0.47% on the day, amid a bearish technical signal and mixed earnings performance. The company reported strong revenue growth to $605.49M in 2025 with a net income margin of 22.69%, but recent quarters have seen earnings misses. Analyst sentiment remains positive with a consensus price target of $99.75 and a 69% buy rating, though news flow includes investigations into fiduciary duties.
The outlook balances robust fundamentals against near-term headwinds. Upside potential exists from the high analyst target and strong profitability metrics like a 36.28% ROE, but risks include earnings volatility, margin pressure, and ongoing legal scrutiny. The stock's current valuation at a P/E of 20.47 offers a reasonable entry if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Teradyne, Inc.
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
